From the Journal

“Very” Very Late Stent Thrombosis: Acute Myocardial Infarction From Drug-Eluting Stent Thrombosis More Than 5 Years After Implantation

Antony Kaliyadan, MD;  Henry Siu, MD;  David L. Fischman, MD;  Nicholas J. Ruggiero II, MD;  

Babu Jasti, MD;  Paul Walinsky, MD;  J. David Ogilby, MD;  Michael P. Savage, MD

A serious long-term complication of drug-eluting stent (DES) implantation is the occurrence of very late stent thrombosis beyond 1 year after implantation. We identified a series of patients who presented with acute myocardial infarction due to stent thrombosis more than 5 years after DES implantation and found that the risk persists even beyond 5 years after first-generation DES implantation. ...

Topics: 

Insights Into Very Late Stent Thrombosis From the Wisdom of Pathology

Kazuyuki Yahagi, MD;  Michael Joner, MD;  Renu Virmani, MD

A thoughtful commentary on the evolution of stent technology and resulting complications, as pertaining to this month’s article by Kaliyadan, et al....

Topics: 

High Femoral Artery Bifurcation Predicts Contralateral High Bifurcation: Implications for Complex Percutaneous Cardiovascular Procedures Requiring Large Caliber and/or Dual Access

Vipul Gupta, MD1;  Kent Feng, BS1;  Pavan Cheruvu, MD1;  Nathan Boyer, MD1

Yerem Yeghiazarians, MD1;  Thomas A. Ports, MD1;  Jeffrey Zimmet, MD, PhD1

Kendrick Shunk, MD, PhD1;  Andrew J. Boyle, MBBS, PhD1,2

Recent technological advances have led to increased use of bilateral femoral artery access and the requirement for large-bore access. Our study examines the relationship between bifurcation level of one CFA and the contralateral CFA in order to better define the prevalence of high bifurcation of the CFA and the relationship between bifurcation level on both sides. ...

Clinical Outcomes in the Percutaneous Coronary Intervention of In-Stent Restenosis With Everolimus-Eluting Stents

Michael S. Lee, MD1;  Tae Yang, MD1;  Ehtisham Mahmud, MD2;  Kyung Woo Park, MD3;  

Hyo-Soo Kim, MD3;  Moo Hyun Kim, MD4;  George Dangas, MD5;  James Hermiller, MD6;  

Mitchell Krucoff, MD7;  David Rutledge, PharmD8

Xience V USA is a prospective multicenter registry evaluating outcomes in patients treated with EES. Here, we present the 12-month clinical outcomes in patients who received EES for the treatment of in-stent restenosis (ISR) and non-ISR.     ...

Topics: 

Back to top